Medicare and Medicaid are projected to cover $263 billion in health care, long-term care, and hospice costs for Americans age 65 and older with Alzheimer’s disease or other dementias in 2026. That represents 64% of the projected $409 billion total, while out-of-pocket spending is expected to reach $103 billion, or 25%. These figures are projections, not final observed spending or a federal appropriation.
They also do not represent Medicare and Medicaid dementia programs alone. For example, the $409 billion estimate combines hospital care, physician services, long-term care, hospice, and other paid care for older people with dementia; it excludes the substantial value of care provided without pay by family members and friends. The estimate comes from the 2026 Alzheimer’s Disease Facts and Figures report, first published April 21, 2026, and corrected July 5, 2026. Its scope matters because describing the $263 billion as “Medicare spending on dementia” would incorrectly combine two public programs with different responsibilities.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check Medicare coverage for a cognitive assessment and dementia care plan — Verify what Part B covers, expected cost sharing, and how to ask a provider about GUIDE support.
- Review Medicaid help available alongside Medicare — See how Medicaid can help eligible Medicare beneficiaries with costs and longer-term services.
Table of Contents
- What Does Medicare and Medicaid Dementia Spending in 2026 Include?
- Why Medicare and Medicaid Pay for Different Types of Dementia Care
- How Out-of-Pocket Dementia Costs Fit Into the 2026 Projection
- How Families Can Check Coverage and Control Care Costs
- GUIDE Model Benefits, Limits, and Eligibility Rules
- What Leqembi’s Approval Means for Dementia Spending
- Reading the 2026 Dementia Spending Numbers Accurately
- Frequently Asked Questions
What Does Medicare and Medicaid Dementia Spending in 2026 Include?
The projected $409 billion covers payments for health care, long-term care, and hospice for people age 65 and older with Alzheimer’s or other dementias. Medicare and Medicaid together account for an estimated $263 billion, but the published combined figure does not mean that every dollar paid by either program is labeled as a dementia-specific expense. A person with dementia may generate costs across several settings. Medicare might pay for an inpatient admission after a fall, physician visits, diagnostic services, and a limited period of qualifying skilled nursing care.
Medicaid might later pay for long-term nursing-facility care if the person meets financial, functional, and state eligibility requirements. The comparison with people who do not have dementia illustrates the scale of the burden. Average annual Medicare payments for beneficiaries age 65 and older with Alzheimer’s or another dementia are nearly three times those for beneficiaries without these conditions. Average Medicaid payments are more than 22 times higher, reflecting Medicaid’s major role in long-term services and supports.
Why Medicare and Medicaid Pay for Different Types of Dementia Care
medicare is primarily a health insurance program. It generally pays for medically necessary hospital, physician, outpatient, home health, hospice, and qualifying short-term skilled nursing services under its normal coverage rules. It does not become a comprehensive long-term custodial-care benefit simply because someone has dementia. Medicaid is the principal national payer for long-term care.
For people enrolled in both Medicare and Medicaid, Medicare pays first for services covered by both programs. Medicaid may then cover additional services, including nursing-facility care after Medicare’s skilled-nursing coverage ends. Families should not assume that a dementia diagnosis automatically creates Medicaid nursing-home coverage. The person must qualify for Medicaid, meet the state’s level-of-care standard, and use a Medicaid-certified facility. States may apply different financial and institutional eligibility rules, so eligibility in one state does not guarantee the same result after a move to another.
How Out-of-Pocket Dementia Costs Fit Into the 2026 Projection
Out-of-pocket payments are projected at $103 billion in 2026, equal to 25% of the estimated total. These payments can include deductibles, coinsurance, premiums, uncovered long-term care, and other expenses paid directly by patients or families. General Medicare cost sharing can add to that burden even though the amounts are not dementia-specific.
In 2026, the standard Medicare Part B premium is $202.90 per month, the Part B deductible is $283, and the Part A inpatient deductible is $1,736. For example, a beneficiary receiving repeated outpatient evaluations may owe the Part B premium, deductible, and applicable coinsurance under ordinary Medicare rules. A later hospital admission may trigger Part A cost sharing. If the person then needs ongoing supervision or personal assistance that Medicare does not cover, the family may face additional private-pay costs unless Medicaid or another source provides coverage.
How Families Can Check Coverage and Control Care Costs
Families can begin by separating medical care from long-term assistance. Hospital treatment, physician care, and qualifying rehabilitation generally belong in the Medicare category. Extended help with bathing, dressing, eating, supervision, or residence in a nursing facility may require Medicaid eligibility, private payment, long-term-care insurance, or a combination of resources. People enrolled in both Medicare and Medicaid should ask which program pays first, whether the provider accepts both programs, and whether a service requires prior authorization.
For nursing-facility care, families should confirm that the facility is Medicaid-certified before assuming Medicaid can pay after private funds decline. There is often a tradeoff between immediate placement and preserving future options. A family may find a private-pay residence with an available room, but that residence may not participate in Medicaid. A Medicaid-certified nursing facility may offer a possible path to public coverage, yet admission still depends on clinical criteria, financial eligibility, available beds, and state rules.
GUIDE Model Benefits, Limits, and Eligibility Rules
The Guiding an Improved Dementia Experience, or GUIDE, Model is an active Medicare demonstration designed to support coordinated dementia care and caregivers. The voluntary nationwide model began July 1, 2024, and is scheduled to run for eight years. It is a model test involving participating providers, not a universal dementia entitlement available through every Medicare practice. CMS pays participating providers a tiered monthly dementia-care-management payment adjusted for geography and performance. The model can also reimburse eligible respite services up to $2,500 annually per patient, adjusted for inflation.
Participating providers may not charge aligned patients cost sharing for GUIDE services. Eligibility is limited. A patient must have clinician-confirmed dementia, have Original Medicare Parts A and B with Medicare as the primary payer, and live in a private residence or an approved residential care community. People enrolled in Medicare Advantage, PACE, hospice, or long-term nursing-home care are excluded, as are residents of memory-care units. Beginning July 1, 2026, patients in residential care communities must receive GUIDE services through an approved provider partnership.
What Leqembi’s Approval Means for Dementia Spending
Leqembi, or lecanemab-irmb, is not awaiting FDA approval. The FDA granted it traditional approval on July 6, 2023.
It is an intravenous amyloid-beta antibody for Alzheimer’s disease, and treatment should be initiated only in the early population that was studied: people with mild cognitive impairment or mild Alzheimer’s dementia. A person with moderate or advanced dementia should not assume that the existence of an approved Alzheimer’s drug makes the treatment appropriate. Drug approval, clinical eligibility, Medicare coverage rules, infusion services, monitoring, and patient cost sharing are separate questions that require an individualized review.
Reading the 2026 Dementia Spending Numbers Accurately
The $263 billion estimate should be described as the projected combined Medicare and Medicaid share of broader paid care for older Americans with Alzheimer’s or other dementias. It should not be reported as Medicare-only spending, a dementia-program appropriation, or a final accounting of claims paid during 2026.
The projection also leaves unpaid caregiving outside the $409 billion total. If an adult daughter reduces her work hours to supervise a parent, prepare meals, manage medications, and arrange appointments without compensation, the value of her time is not included in the stated spending figure.
Frequently Asked Questions
Is $409 billion the final amount spent on dementia care in 2026?
No. It is a 2026 projection for health care, long-term care, and hospice payments for Americans age 65 and older with Alzheimer’s or other dementias. It is not a final claims total.
Does Medicare alone account for $263 billion?
No. The $263 billion figure combines projected Medicare and Medicaid payments and represents 64% of the $409 billion total.
Does Medicare pay for permanent nursing-home care for dementia?
Medicare may cover qualifying short-term skilled nursing care, but it is not a general permanent custodial-care benefit. Medicaid may cover longer-term nursing-facility care for eligible people in Medicaid-certified facilities.
Does a dementia diagnosis guarantee Medicaid coverage?
No. Applicants must meet Medicaid eligibility requirements and state level-of-care criteria. State financial and institutional rules can differ.
Is GUIDE available to people with Medicare Advantage?
No. GUIDE eligibility requires Original Medicare Parts A and B with Medicare as the primary payer. Other exclusions include PACE, hospice, long-term nursing-home residence, and residence in a memory-care unit.
Is unpaid family caregiving included in the $409 billion projection?
No. The estimate excludes informal or unpaid caregiving.
